A biopharmaceutical company focused on novel drug discovery
Total raised: $45M
Investors 3
Funding Rounds 1
Date | Series | Amount | Investors |
- | Series C | $45M | - |
Mentions in press and media 2
Date | Title | Description | Source |
18.03.2024 | KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-08... | -- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from ... | en.prnasia... |
- | Chinese Biopharmaceutical Firm KeChow Pharma Closes on $45M ... | - | qimingvc.c... |